Graham Taylor has previously received funding from Cancer Research UK, Blood Cancer UK, the UK Medical Research Council, Melanoma UK, and the University of Birmingham to support his research team.

Detailed mapping of CD4⁺ T cells from children with systemic lupus erythematosus (SLE) has revealed distinct immune cell subsets with likely roles in disease pathogenesis, according to a study led by ...

Scientists have found the clearest evidence yet that Epstein-Barr virus (EBV) – which nearly all of us carry for life – is directly responsible for hijacking our immune system's cells to cause lupus, ...

Nearly all adults carry Epstein–Barr virus—but new research reveals how it can hijack immune cells, sparking a chronic disease that attacks the body from within. This colorized transmission electron ...

One of the most common viruses in the world could be the cause of lupus, an autoimmune disease with wide-ranging symptoms, according to a study published Wednesday. Until now, lupus was somewhat ...

Holly has a degree in Medical Biochemistry from the University of Leicester. Her scientific interests include genomics, personalized medicine, and bioethics.View full profile Holly has a degree in ...

For years scientists have suspected that the Epstein-Barr virus (EBV)—a type of herpesvirus that infects 94 percent of the global population by adulthood and causes mononucleosis (aka “mono”)—might be ...

The virus behind glandular fever, also known as mononucleosis or kissing disease, seems to infect and reprogram immune cells in the body, priming some people to develop the autoimmune condition lupus.

A newly discovered molecule may hold the key to rebalancing the immune system in lupus and autoimmune diseases. A newly discovered molecule may hold the key to rebalancing the immune system in lupus ...

With the lupus treatment landscape poised for a shake-up, Roche is hitting the scene in the U.S. with a new green light for its long-approved blood cancer medicine Gazyva. Early Monday, Roche’s ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved obinutuzumab for the treatment of adults with active lupus nephritis who are receiving ...